Investigational drug · Phase 2
SYS6041
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Recurrent Ovarian Cancer, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "SYS6041"
First trial start
2025
Mar 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6041", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Recurrent Ovarian Cancer
- Advanced Solid Tumors
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6041" as an intervention, largest first.
- A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07744763 · 260 participants (planned) · Start Mar 28, 2025 · Primary completion Mar 28, 2027
Drug: SYS6041 · For: Advanced Solid Tumors
Sites: Shanghai, China
- A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerPivotal-lookingRecruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07714668 · 171 participants (planned) · Start Aug 13, 2026 · Primary completion Apr 30, 2028
Drug: SYS6041, bevacizumab; SYS6041, carboplatin, bevacizumab and 2 more · For: Ovarian Cancer; Recurrent Ovarian Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.